Firouzeh Korangy

Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver Transplantation

Lorenz Kocheise, Gabriel Bacil, Pavan Bhimalli, Mohamed-Reda Benmebarek et autres

Abstract Background & Aims Liver transplantation improves outcomes in hepatocellular carcinoma (HCC), yet treatment options for patients with tumor recurrence remain limited to tyrosine kinase inhibitors. Glypican-3 (GPC3)-targeted CAR T cells offer a tumor-directed immune-based therapeutic strategy, but their efficacy may be …

us (code pays fourni par la source)

Abstract 1585: Kinetic profiling of ILC and ILTC responses during early hepatocellular carcinoma development reveals IL-15-ILC1 axis

Patrick Huang, Rajiv Trehan, Benjamin Ruf, Chi Ma et autres

Abstract Cancer immunotherapy has largely focused on conventional T cells due to their recognition of precise peptide-antigens. However, despite recent breakthroughs, including the adoption of immune checkpoint inhibitor therapy as first-line therapy for unresectable hepatocellular carcinoma (HCC), the overall mortality associated with …

us, de (code pays fourni par la source)

Targeting mucosal-associated invariant T cells using riboflavin metabolism derived TCR ligands for innate immunotherapy of liver cancer

T J Krpicak, Pei Huang, Chi Ma, Rajiv Trehan et autres

Introduction: Mucosal-associated invariant T (MAIT) cells are an abundant T cell subset in the human liver and they play a crucial role in the regulation of immunity and inflammation. MAIT cells can be activated and expanded using riboflavin metabolism-derived T cell receptor …

de, us (code pays fourni par la source)

SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases

Rajiv Trehan, Patrick Huang, Xiao Bin Zhu, Xin Wang et autres

Functional tumor-specific CD8+ T cells are essential for effective anti-tumor immune response and immune checkpoint inhibitor therapy. Here we show that, compared to other organ sites, primary, metastatic liver tumors in murine models contain a higher number of tumor-specific CD8+ T cells …

us (code pays fourni par la source)

Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME

Mohamed-Reda Benmebarek, Cihan Oguz, Matthias Seifert, Benjamin Ruf et autres

us (code pays fourni par la source)

Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab

Yuta Myojin, Sepideh Babaei, Rajiv Trehan, Noémi Kedei et autres

BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC. OBJECTIVE: To study immune responses in HCC patients treated with tremelimumab and durvalumab. DESIGN: We treated …

us, de, ie (code pays fourni par la source)

Activating Mucosal-Associated Invariant T (MAIT) cells for next generation immunotherapy of liver cancer

Benjamin Ruf, Patrick Huang, Chi Ma, Mohamed-Reda Benmebarek et autres

Introduction: Mucosal-associated invariant T (MAIT) cells represent up to 30-40% of T cells in the liver and they play a crucial role in the regulation of immunity and inflammation. We have recently shown that MAIT cells can contribute to anti-tumor activity in …

us (code pays fourni par la source)

A Paradoxical Tumor Antigen Specific Response in the Liver

Rajiv Trehan, Xiao Bin Zhu, Patrick Huang, Xin Wei Wang et autres

Abstract Functional tumor-specific CD8+ T cells are essential for an effective anti-tumor immune response and the efficacy of immune checkpoint inhibitor therapy. In comparison to other organ sites, we found higher numbers of tumor-specific CD8+ T cells in primary, metastatic liver tumors …

us (code pays fourni par la source)

Aktivierung von Mucosal-Associated Invariant T (MAIT) Zellen zur Next Generation Immuntherapie von Leberkrebs

Benjamin Ruf, Patrick Huang, Chi Ma, Vanessa V. Catania et autres

Einleitung: Immuntherapien, die konventionelle T-Zellen aktivieren, haben die systemische Behandlung vieler Krebsarten revolutioniert, doch nur ein Teil der Patienten profitiert von diesen Ansätzen. MAIT repräsentieren bis zu 30-40% der T-Zellen in der Leber und zählen zu den sog. unkonventionellen oder innate-like T-Zellen. …

us, de (code pays fourni par la source)

Abstract 3970: Impairment of tumor reactive CD8 T cells in liver cancer

Rajiv Trehan, Marlaine Soliman, Xin Wei Wang, Patrick Huang et autres

Abstract Tumor reactive (TR) CD8 T cells in the liver have been studied in the setting of both immunotherapy and cellular therapy with the predominant dogma that these cells have equivalent functionality in the liver as compared to other organ sites. Herein, …

us (code pays fourni par la source)

Abstract 2694: The role of innate lymphoid cells and innate like T cells in hepatocellular carcinoma

Patrick Huang, Benjamin Ruf, Rajiv Trehan, Dana Q. M. Soika et autres

Abstract The major focus of cancer immunotherapy has been on conventional T cells due to their unique recognition of specific peptide antigens. Despite advances in the cancer immunotherapy field, including the use of atezolizumab and bevacizumab as first-line therapy for unresectable hepatocellular …

us (code pays fourni par la source)

The Gut Microbiome Controls Liver Tumors via the Vagus Nerve

Kylynda C. Bauer, Rajiv Trehan, Benjamin Ruf, Yuta Myojin et autres

Abstract Liver cancer ranks amongst the deadliest cancers. Nerves have emerged as an understudied regulator of tumor progression. The parasympathetic vagus nerve influences systemic immunity via acetylcholine (ACh). Whether cholinergic neuroimmune interactions influence hepatocellular carcinoma (HCC) remains uncertain. Liver denervation via hepatic …

us (code pays fourni par la source)